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Epithelial ovarian cancer (EOC) is an immunologically active malignancy, but thus far immune therapy has had
limited success in clinical trials. One barrier to implementation of efficacious immune therapies is a lack of
knowledge of the effect of chemotherapy on the monocyte-derived component of the immune infiltrate within
the tumor. We utilized the ID8 murine EOC model to investigate alterations within tumor ascites that occur
following administration of platinum chemotherapy. Cisplatin treatment resulted in a significant increase in
monocytes within the ascites of tumor bearing mice. We identified that CD11b+ cells from the ascites of mice that
have been treated with cisplatin elicits an increase in IFN-ɣ expression from CD8+ T-cells compared to CD11b+
cells from a mouse treated with vehicle control (604.0 pg/mL v. 4328.0 pg/mL; p < .0001). Splenocytes derived
from tumor bearing mice released increase levels of IFN-ɣ after treatment with cisplatin when incubated with
dendritic cells (DCs) and tumor antigen (62.0 v. 92.1 pg/mL; p = .03). Cisplatin induced an increase in T-cell and
monocyte/macrophage activation markers (CD62L and CD301). Levels of IL-10, IL-6, and VEGF in the cell free
ascites of mice treated with cisplatin decreased (p > .05). These results indicate that treatment with cisplatin
leads to an increase of anti-tumor activity within the ascites related to alterations in the ascites monocytes.
Further investigation of these findings in humans is necessary to identify how these cells behave in different
patient subgroups and if there is a role for monocyte directed therapy in conjunction with T-cell directed therapy
and/or chemotherapy.

Introduction
Epithelial ovarian cancer (EOC) remains the most deadly gyneco
logic malignancy in North America with a 5 year overall survival rate of
29% in women diagnosed with advanced stage disease [1]. Studies of
human specimens of EOC have shown that this is an immunologically
active cancer and that women with intra-tumoral cytotoxic T-cells have
a more favorable prognosis [2–4]. Despite the prognostic relationship
between the tumor and immune system, immunotherapies have thus far
had limited efficacy in treating women with EOC [5,6]. Prior studies
have demonstrated that many of the cell populations necessary to mount
an anti-tumor immune response including antigen-presenting cells,
neutrophils, and cytotoxic CD8+T-cells can be found within the tumor
and surrounding stroma, as well as within the peripheral blood of
women with EOC, but that these cell populations are inhibited by the
presence of tumor cells, immunosuppressive immune cells, and

immunosuppressive cytokines within the ovarian cancer and ascites
fluid [7–11]. This phenomenon suggests that the tumor alters the im
mune milieu within the tumor microenvironment (TME) resulting in
protection from immune surveillance and attack. Studies have shown
that this is accomplished at least in part by myeloid-derived suppressor
cells (MDSC), including tumor associated macrophages and immuno
suppressive neutrophils, as an intermediary between the tumor cells and
effective T-cell mediated immune responses [7,12–14].
Importantly, while our understanding of the immune status of un
treated EOC is broadening; little is known about the effects of chemo
therapy on the immune cells within the TME. Patients enrolled in
immune therapy clinical trials are often enrolled following or in
conjunction with chemotherapy, but tumor characteristics are based on
pre-treatment tumor specimens. Platinum based chemotherapy is the
standard care for adjuvant treatment of EOC [15]. Interestingly, recent
clinical studies of the immune cells within the TME of EOC patients have
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shown paradoxical changes to the T-cell population in the TME
comparing pre and post chemotherapy specimens. Specifically, there is
an increase in cytotoxic T-cells within the TME and shifts in immune
related cytokines favoring an anti-tumor immune activation that co
incides with an increase in check point marker expression [16–19].
Changes that occur with chemotherapy administration in the monocyte
population within the TME is largely unknown. Given the role mono
cytes play in untreated tumors, we sought to further elucidate the
changes that occur in the monocytes within the ascites when treated
with chemotherapy and how those changes may lead to downstream
effects on T-cells and the TME.
To address the gap in our understanding of the alterations seen in
monocytes with chemotherapy we utilize the ID8 murine model of EOC
to explore the alterations that occur in the monocytes, T-cells, and cy
tokines within the ascites following treatment with cisplatin chemo
therapy. We have identified both phenotypic changes and alterations in
the activity of cells in the TME as a result of chemotherapy that includes
activation of monocytes to a pro-inflammatory state and tumor specific
T-cell activation that occurs following cisplatin treatment. Our findings
suggest that monocytes remain an integral component of the TME in
response to chemotherapy and may be manipulated as a treatment
strategy to improve patient outcomes.

tumor bearing mice. To ensure consistent extraction, the peritoneal
cavity was lavaged with 3cc normal saline. All obtainable peritoneal
fluid was then harvested through an 18 g syringe and utilized for assays.
Ascites was centrifuged and the cell free supernatant was collected for
cytokine analysis. The cell pellet was treated with ACK lysis buffer (0.15
M NH4Cl, 1.0 mM KHCO3, 0.1 mM EDTA) to lyse red blood cells. A single
cell suspension of splenocytes was obtained with a 70 µM cell strainer
(BD bioscience, San Jose, CA). The suspension was then treated with
ACK lysis buffer and washed. CD8+ T-cells and CD11b+ leukocytes were
isolated using bead isolation kits (Miltenyi Biotech, Auburn, CA) per
manufacturer’s protocol.
FACS
Tumor ascites was prepared as described above. Murine antibodies to
Ly6g, Ly6c, CD11b, CD4, CD8, CD45, CD301 and CD62L were purchased
from BioLegend (SanDiego, CA). Anti CD44 was purchased from Abcam
(Cambridge, MA). 100 µL aliquots of single cell suspensions were pre
pared. Fc receptors were blocked by adding 1 µg purified anti-CD16/32
clone 2.4G2 per aliquot (Bioxcell, Lebanon, NH). Brilliant blue buffer
(BD Biosciences, San Jose, CA) was also added to improve resolution of
Brilliant Violet polymer dyes. Pre-titrated fluorophore antibodies were
added, gently mixed, and incubated while shaking at room temperature
for 30 min. Aliquots were then washed and the cell pellet was resuspended in 200µL 2% paraformaldehyde fixative. Following fixation,
the paraformaldehyde was washed out and the cell pellet was resuspended in 200 µl PBS Ca/Mg free (SigmaAldrich, St. Louis, MO).
Fluorescence acquisition was done on a Miltenyi MacsQuant 10 flow
cytometer (Miltenyi Biotech) at optimized settings and flow rate. The
flow data was analyzed utilizing FlowJo software (Ashland, OR). To gate
on monocyte cells large cells were selected on forward and side scatter.
This population was then further refined by eliminating cell doublets.
The 11b/45 dual positive population was selected. From this subset the
Ly6C+ and Ly6Gd− population was identified as the cell population of
interest. Similarly cells within the size range of monocytes that were F4/
80+ were selected and assessed for CD301. T-cells were identified by
selecting the relevant subset on forward and side scatter. CD8+ T-cells
were considered cells that were CD45+/CD4− /CD8+.

Methods
Mice and cell lines
Five to six week old female C57BL/6 mice were purchased from
Charles River (Wilmington, MA). CCR2 knock out (CCR2ko) mice were
purchased from Jackson Laboratory (Bar Harbor, ME). OT-1 mice were
generously provided by the lab of Dr. Mary Jo Turk (Geisel School of
Medicine, Lebanon, NH). All animal experiments were approved by the
Institutional Animal Care and Use Committee.
The murine ID8 ovarian tumor model is syngeneic with C57BL/6
mice [20]. Generation of ID8 murine ovarian cancer cells transduced
with pFB-neoLuciferase (ID8-luc cells) were previously described [20,
21]. ID8 cells transfected to express ovalbumin (ID8-ova) were kindly
provided by Dr. Mary Jo Turk [22]. Intra-peritoneal tumor and ascites
were induced by injecting 5 × 106 ID8-luc or ID8-ova cells
intra-peritoneal (i.p.) into 5–6 week old mice. Following ID8-luc injec
tion, mice were imaged for in vivo luciferase activity 4 weeks following
inoculation. To image the mice, they were injected i.p. with 200 µL of 15
mg/mL D-Luciferin Potassium Salt (Gold Biotechnology, St. Louis, MI) in
nine percent sodium chloride (Baxter, Deerfield, IL). Mice were then
sedated with isoflurane gas. Images were obtained 10 min after Luciferin
injection with the Xenogen VivoVision IVIS Bioluminescent and Fluo
rescent Imager (PerkinElmer, Waltham, MA). Cisplatin (SigmaAldrich,
St. Louis, MO) therapy was initiated once mice expressed multiple sites
of intra-peritoneal disease on imaging or following evidence of ascites in
the ID8 ova model. Cisplatin was injected i.p. twice weekly at a dose of 2
mg/kg. Mice were treated for 3–4 weeks.
The bone marrow-derived dendritic cell (BMDC) culture protocol has
been previously described [22]. In summary bone marrow-derived cells
from OT-1 mice were suspended in DC media (RPMI 1640 medium, 10%
heat-inactivated
fetal/bovine
serum,
100
units/ml
pen
icillin/streptomycin, 50 mM B-mercaptoethanol, 10% conditioned su
pernatant from X63 cells secreting GM-CSF). Cells were plated in a
24-well tissue culture plate at 106 cells in one milliliter medium per
plate. On days 2 and 4, the cells were washed and re-fed, and
non-adherent cells removed. Semi-adherent cells were harvested on day
six, which were phenotypically confirmed to be immature DCs by flow
cytometry.

Luminex
Cell free ascites was collected as described above. Simultaneous
determination of multiple cytokine concentrations was carried out by
the Dart Lab Core Facility at the Norris Cotton Cancer Center (NCCC) on
cell free ascites using the MILLIPLEX MAP Mouse/human Cytokine/
Chemokine Magnetic Bead Panel— Premixed 32/41 Plex (EMD Milli
pore, Billerica, MA) on a Bio-Rad Bio-Plex Array Reader. Samples were
diluted in cell culture medium to the dynamic range of each kit.
Interferon-gamma (IFN-ɣ) ELISA
To quantitatively measure induction of INF-ɣ, 1 × 105 CD11b+ cells
or cultured dendritic cells were combined with 1 × 106 CD8+ T-cells or
splenocytes. CD11b+cells and CD8+ T-cells with incubated with 50 nM
PMA and 0.5 µM ionomycin (Sigma, St. Louis, MO). Cultured dendritic
cells and splenocytes, from OT-1 mice were plated with 1 µg/mL SIIN
FEKL peptide. Three wells were plated for each sample. Cell-free su
pernatants were collected after 48 h of incubation and production of
IFN-ɣ cytokines was quantitated by ELISA. DuoSet enzyme-linked
immunosorbent assay (ELISA) kits for mouse INF-ɣ were acquired
from R&D Systems (Minneapolis, MN). IFN-ɣ quantity was then derived
from a standard curve of serial dilutions per the manufacturer’s
directions.

Tumor, splenocyte, and leukocyte isolation
Murine ascites was obtained from the peritoneal cavity of euthanized
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Statistics

of mice carrying ID8 EOC. In addition we show that the percentage of
CD8+ T-cells in the ascites decreases in the presence of cisplatin
treatment.

All data was analyzed using Prism Graph Pad Software (San Diego,
CA), with p < 0.05 considered statistically significant. Values were
compared using a two-tailed Students t-test. All assays were at least
replicated. Experiments had 4–6 mice per experimental group.

In vivo cisplatin chemotherapy of ID8 ovarian cancer increases the ability
of ascites-derived CD11b+ cells to induce T-cell stimulation

Results

To assess the function of the CD11b+ cells within tumor ascites and
the potential downstream effect of an increase in CD11b+ monocytes,
CD11b+ cells from mice treated with vehicle control or cisplatin were
isolated and tested for their quantitative ability to elicit a CD8+ T-cell
response. CD11b+ cells were isolated from ID8 tumor ascites, and then
combined with naive CD8+ T-cells from non-tumor bearing mice and
incubated for 48 h in the presence of ionomycin and PMA after which
IFN-ɣ levels in the cell-free media was measured (Fig. 2). CD8+ T-cells
stimulated by tumor associated CD11b+ cells derived from mice who
were treated with vehicle control elicited 604.0 (±52.92) pg/mL of IFNɣ. In comparison, CD8+T-cells stimulated by CD11b+ cells from mice
treated with cisplatin were elicited 4328.0 (±185.2) pg/mL of IFN-ɣ (p
< .0001). Negative and positive experimental controls of un-stimulated
T-cells and T-cells stimulated in the absence of CD11b+ cells, respec
tively, are shown (Fig. 2). These findings demonstrate that not only does
the concentration of CD11b+ cells increase with cisplatin chemotherapy,
but that it fundamentally alters the functional ability of these cells.
Specifically, in vivo cisplatin treatment results in CD11b+ cells within
the TME that are able to induce significantly higher levels of IFN-ɣ from
CD8+T-cells compared to CD11b+ cells from mice that have not un
dergone chemotherapy.

Treatment with cisplatin induces an influx of monocytes and decreases
cytotoxic T-cells
In order to determine the changes in the LygC+/Ly6G− monocyte
population and CD8+ T-cell population that occur with chemotherapy,
we employed the murine ID8 ovarian tumor model, which recapitulates
critical characteristics of human epithelial ovarian cancer including a
progressive accumulation of ascites, an immunosuppressive TME, and
the recruitment of leukocytes including a substantial population of
monocytic MDSC [14,20]. Tumor bearing C57BL/6 mice were treated
with cisplatin or vehicle control twice weekly by i.p. injection. CCR2ko
mice were used as a control for peritoneal monocyte recruitment [23,
24]. Monocytic cells were classified as CD45+, 11b+, Ly6c+, and Ly6g−
[25]. Tumor bearing wild type mice treated with cisplatin had an in
crease in the percentage of monocytes within their ascites compared to
tumor bearing mice treated with vehicle control (Fig. 1A, p < .0001, CI
19.80–29.90). In mice treated with vehicle control, 9.35% ± 1.37 of
CD45+ ascites cells stained as monocytes. In mice treated with cisplatin,
monocytes composed 34.2% ± 5.32 of the ascites cell population. CCR2
has previously been identified as key cytokine receptor responsible for
the recruitment of monocytic cells to the ovarian cancer TME, and
therefore we used CCR2ko (CCR2− /− ) mice, in parallel, as an internal
control for specificity of cellular recruitment [14]. In CCR2ko mice
treated with vehicle control only 1.84% ± 0.48 of the cells within the
ascites were classified as monocytes, less than both the control and
cisplatin groups (p < .0001). The percentage of CD45+/CD8+ T-cells
within the ascites decrease from 7.44% ± 1.6 to 3.11% ± 1.08 (p = .004)
in the setting of cisplatin treatment (Fig. 1B). These findings support that
treatment with cisplatin leads to an influx of monocytes into the ascites

In vivo cisplatin treatment of ID8 tumor-bearing mice results in a proinflammatory tumor microenvironment
To identify how in vivo cisplatin treatment of ID8 tumors alters the
inflammatory state of the TME, we analyzed cellular and inflammatory
markers from ascites. Ascites was harvested from ID8 tumor bearing
mice that had undergone either cisplatin or control treatment. Luminex
was used to quantify the concentrations of IL-10, VEGF, and IL-6, cy
tokines associated with immune suppression, within the cell free ascites

Fig. 1. In vivo cisplatin treatment of murine ID8 ovarian tumors results in increased Ly6C+monocyte recruitment to the tumor microenvironment and a decrease in
CD8+ T-cells. In order to determine the changes in the Ly6c+ monocyte and cytotoxic T-cell population that occurred with chemotherapy, tumor bearing C57BL/6
(4–6 mice per group) were treated with cisplatin or vehicle control. CCR2ko mice were used as a control. In Fig. 1A monocytes were classified as CD45+, 11b+,
Ly6c+, and Ly6g-. We found that in wild type C57BL/6 mice that did not receive cisplatin the percentage cells that stained as monocytes was 9.35% ± 1.37. In wild
type C57BL/6 that were treated with cisplatin monocytes composed 34.2% ± 5.32 of the cell population. The difference between these groups is statistically sig
nificant (p < .0001, CI 19.80–29.90). In CCR2 knock out mice treated with vehicle control only 1.84% ± 0.48 stained as monocytes. This is significant less than both
the control and cisplatin groups (p < .0001). In Fig. 1B CD8+ T-cells showed a relative decrease in the ascites following cisplatin therapy from 7.44% ± 1.6 to 3.11%
± 1.08 (p = .004). These findings indicate that treatment with cisplatin leads to an influx of Ly6c+ monocytes and a decrease of CD8+ T-cells into the malignant
ascites of mice carrying ID8 epithelial ovarian cancer. Additionally, CCR2 is a key component in the recruitment of the Ly6c+ cell population into the ascites. (*=p <
.05; ctrl=control group; CIS tx=group treated with cisplatin.
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Fig. 2. CD11b+ cells from the ascites of mice treated
with cisplatin activate CD8+ T-cell more effectively
than CD11b+ cells from untreated mice. In order to
identify the mechanistic nature of CD11b+ cells
recruited to the ascites we isolated this cell population
from the ascites of tumor bearing mice treated with
vehicle control or cisplatin (4–6 mice per group). The
CD11b+ cells were then combined with CD8+ T-cells
of non-tumor bearing mice and incubated for 48 h after
which IFN-ɣ levels in the cell free media was measured.
The first two columns represent positive and negative
controls respectively. The combination of CD11b cells
from tumor bearing mice that were treated with vehicle
control and T-cells elicited 604.0 (±52.92) pg/mL of
IFN-ɣ. When CD11b cells from tumor bearing mice
treated with cisplatin were combined with T-cells they
elicited 4328.0 (±185.2) pg/mL of IFN-ɣ. CD11b+ cells
in mice receiving chemotherapy induced significantly
higher levels of IFN-ɣ from T-cells compared to
CD11b+ cells from mice treated with vehicle control
(*=p < .0001).

from mice treated with vehicle control or cisplatin (Fig. 3A,3B, AND 3C
respectively) [13,26]. Within the ascites, mice treated with cisplatin had
lower levels of IL-10 (8.80 ± 7.84 pg/mL) VEGF (10.68 ± 10.77) and
IL-6 (51.21 ± 39.44) compared to those treated with vehicle control
(53.41 ± 37.85 pg/mL IL-10 (p > .05); 1035 ± 1140 pg/mL VEGF; 102.9
± 8.089 IL-6 (p > .05)). These differences were not statistically signifi
cant, but suggest a trend toward a more immunologically active TME

with administration of cisplatin. To determine if this pro-inflammatory
shift in the TME is reflected in the cellular phenotypes, FACS analyses
were performed on single-cell suspensions of cells derived from the as
cites. F4/80+ cells from mice treated with cisplatin had lower levels of
CD301 (MFI = 13,495 ± 6208), a marker of inhibitory macrophages,
compared to mice treated with vehicle control (20,115 ± 5229; p > .05)
(Fig. 3D). In order to further characterize the T-cells recruited to the

Fig. 3. Cytokines and cell markers associated with immune cell activation and burnout indicate an increased in ascites immune activation following cisplatin
treatment. Luminex was used to quantify the immunosuppressive cytokines IL-10, VEGF, and IL-6 within the cell free ascites in mice treated with vehicle control or
cisplatin (Fig. 3A,3B, and 3C respectively) and FACS was used to assess markers of macrophage activation (Fig. 3D), T-cell activation (Fig. 3E), and T-cell burn out
(Fig. 3F). Mice treated with cisplatin had lower levels of IL-10 (8.80 ± 7.84 pg/mL), VEGF (10.68 ± 10.77), and IL-6 (51.21 ± 39.44) in the cell free ascites compared
to those treated with vehicle control (53.41 ± 37.85 pg/mL IL-10; 1035 ± 1140 pg/mL VEGF; 102.9 ± 8.089 IL-6). These differences were non-significant, but
suggest a trend toward a more immunologically active TME with administration of cisplatin. Although non-significant, mice treated with cisplatin had lower levels of
CD301 (13,495 ± 6208) compared to mice treated with vehicle control (20,115 ± 5229) measured by MFI. Although non-significant, expression of CD44, a marker of
T-cell activation, increased with cisplatin therapy (55.9 ± 6.17 v 64.21 ± 10.99) measured by MFI. Additionally, The MFI of CD62L, a marker of CD8 T-cell burn out,
decreased in the ascites of mice treated with cisplatin (24.11 ± 18.75 v 15.60 ± 10.75). Although the difference between the treated and untreated groups did not
reach statistical significance, these assays show a trend towards a more immunologically active TME following administration of chemotherapy.
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tumor ascites we performed FACS analyses for CD 44 or CD 62 L on
ascites-derived CD8+ T cells. The expression of CD44, a marker of T-cell
activation, increased with cisplatin therapy (55.9 ± 6.17 v 64.21 ±
10.99; p > .05) (Fig. 3E). Additionally, expression of CD62L, a marker
that is down regulated following T cell activation, decreased with
cisplatin treatment (24.11 ± 18.75 v 15.60 ± 10.75; p > .05) (Fig. 3F).
Although these differences did not reach statistical significance, they
bolster our other findings indicating that cisplatin induces a
pro-inflammatory state within tumor ascites that enables infiltrating
CD8+ T cell activation.

Discussion
Development and utilization of efficacious immune therapies in EOC
requires understanding the immune status of a patient’s tumor and how
the immune milieu changes with the various stages of cancer treatment.
Many ovarian cancers have immune infiltrates present at the time of
diagnosis with the cells favoring a tumor-protective environment. Cur
rent research supports that the immune balance within tumors of un
treated patients is primarily driven by the tumor cells [7–11]. The
changes that take place with respect to the immune infiltrate as a tumor
goes through chemotherapy, regression, and then eventual recurrence
are not as well understood, but are key to the design and implementation
of effective immune therapies. Furthermore, studies in humans on the
effect of chemotherapy on the intra-tumoral immune environment
suggest that even within the same histologic subgroup, the immune
changes within the tumor can be drastically different between patients
[16,17].
Thus far, studies of the effect of chemotherapy on tumor immune
infiltrate have focused on the T-cell populations within the TME and PD1 expression. These studies have shown that in patients with a favorable
prognosis, chemotherapy treatment corresponds to an increase in the
ratio of cytotoxic T-cells within the TME. In both human and murine
data there is an accompanying increase in PD-1 or PDL-1 expression
without therapeutic benefit to PD-1/PDL-1 inhibitor co-treatment [16,
17,19,27]. However, the alterations and subsequent role of the mono
cyte population within the TME during treatment with platinum is not
well understood. To help address this question, we present our study of
the immune environment in a murine model of epithelial ovarian cancer
after treatment with a clinically-relevant platinum agent. Our findings
on the phenotype and functional changes of the cytokine and cellular
infiltrate within the ascites demonstrate a compelling shift to an
anti-tumor immune environment that includes an influx of Ly6C+
monocytes and an increase in the ability of CD11b+ monocytic cells
within the TME to stimulate CD8+ T-cells with specificity for tumor
antigen. Prior studies have suggested that intra-tumoral monocytes are
one of the key mediators of the suppressive nature of the anti-tumor
immune activity in treatment naïve patients [7,12–14]. Our data sup
ports the continued importance of monocytes as a driver of the immune
milieu during treatment with chemotherapy.
Our findings add to the emerging literature demonstrating that
macrophage directed immune therapies may be efficacious in the
treatment of EOC. Specifically, a monocyte inhibitor may be most effi
cacious in treatment-naïve patients or in patients who fail to convert to a
M1 phenotype with chemotherapy. Additionally, there may be a group

In vivo cisplatin treatment results in increased tumor-specific T-cell
responses
Finally, we extended the phenotypic inflammatory status of the TME
following cisplatin treatment to functionally assess the impact of this
treatment, and the resultant TME, on T-cell activity. The T-cell response
to antigen presenting cells is a key step in determining the status, and
impact, of the immune environment. In order to identify the effect of
cisplatin treatment on T-cell responses to tumor-specific antigens, we
used the ID8-ova tumor model in which ID8 cells ectopically express
such that SIINFEKL is a pre-determined, tumor-specific antigen. Groups
of mice were subsequently treated with cisplatin or a control. To
quantitatively assess and compare the relative responses, splenocytes
from tumor bearing OT-1 mice were combined with cultured dendritic
cells pulsed with the CD8+ T-cell epitope of ova, SIINFEKL, and cocultured for 48 h. SIINFEKL is a known epitope of CD8+ T-cells there
fore we expected alterations in signal to be driven by CD8+ T-cells [22].
IFN-ɣ levels in the cell free media was assessed by ELISA as a quanti
tative marker of activity. IFN-ɣ elicited from wild type splenocytes were
utilized as a negative control. Ova-pulsed dendritic cells were able to
induce a higher tumor specific T-cell response, measured via IFN-ɣ, from
CD8+ T-cells derived from tumor bearing mice treated with cisplatin
(94.08pg/mL±45.26) compared to mice treated with vehicle control
(62.03 pg/mL ± 34.4) (p = .03). As a negative control, splenocytes from
non-tumor bearing mice, and therefore not expressing the
tumor-specific ova antigen, expressed 32.83 pg/mL ± 10.10 of IFN-ɣ.
This was significantly less than mice treated with cisplatin (p = .03), but
not significantly less than untreated mice (p = .17) (Fig. 4). These
findings indicate that the T-cells recruited to the tumor have increased
anti-tumor activity potential following chemotherapy treatment. In
conjunction with the other data presented here, these findings strongly
support that chemotherapy facilitates de-repression of the anti-tumor
immune environment and tumor-specific CD8+ T cell response.

Fig. 4. Splenocytes from tumor bearing mice treated
with cisplatin released more IFN-ɣ in response to tumor
specific antigens when compared to untreated tumor
bearing mice. In order to identify differences in the
tumor specific activation potential of T-cells recruited
to the ascites we combined splenocytes from OT-1 mice
bearing ID8-ova tumors treated with either cisplatin or
vehicle control (4–6 mice per group) with cultured
dendritic cells pulsed with SIINFEKL. Cells were incu
bated for 48 h after which IFN-ɣ levels in the cell free
media was assessed. In this experiment wild type
splenocytes served as baseline control. Dendritic cells
were able to induce a higher response, measured via
IFN-ɣ, in splenocytes from mice treated with cisplatin
(94.08±45.26) compared to mice treated with vehicle
control (62.03 ± 34.4) ((*)p = .03). The difference
between negative control wild type splenocytes
(32.83±10.1) and untreated OT-1 splenocytes was not
statistically significant ((#) p = .17). These findings
indicate that the splenocytes recruited to the tumor
have more anti-tumor activity potential following
chemotherapy treatment.
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of patients who benefit from further disinhibition of the macrophages
present within their tumor. Cisplatin was chosen to conduct these
studies because it is a standard of care adjuvant chemotherapy agent and
has efficacy when injected into the peritoneum [15]. However, it is
noteworthy that alternative chemotherapies may affect the host immune
response in different ways. Prior studies have shown that chemother
apies with different mechanisms of action such as Gemcitabine or
Liposomal Doxorubicin alter the intra-tumoral immune infiltrates in
different ways. Importantly, some chemotherapies induce
immune-mediated tumor cell death while others do not [28,29]. Thus,
not only do we need to take the patient’s tumor into account, but also the
chemotherapy being used when designing immune treatments.

[8]

[9]
[10]
[11]
[12]

Conclusion

[13]

Given the complexity and redundancy within the immune system it
will likely be necessary to target tumor cells, monocytes, T-cells, and
cytokines at various time points and in various combinations to effec
tively leverage the immune system against EOCs. Our findings utilizing
cisplatin chemotherapy support prior data showing that the immune
infiltrate within a tumor shifts with chemotherapy and this shift is sig
nificant enough that it needs to be accounted for when implementing
immunotherapies. Additionally, our data support consideration of
monocytes as well as T-cells and cytokines as targets for immune ther
apies. Given the diversity of immune responses to chemotherapy within
a single histologic subtype of EOC, additional human studies are needed
to elucidate the combination of tumor characteristics, chemotherapy,
and immune therapy that will result in targeted cancer cell death.
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